Maplight Therapeutics (NASDAQ:MPLT) Trading Up 10.3% – Time to Buy?

Maplight Therapeutics, Inc. (NASDAQ:MPLT)’s stock price rose 10.3% during trading on Thursday . The stock traded as high as $18.75 and last traded at $18.67. Approximately 324,267 shares traded hands during mid-day trading, an increase of 16% from the average daily volume of 278,857 shares. The stock had previously closed at $16.92.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Leerink Partners started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set an “outperform” rating and a $30.00 price objective on the stock. Jefferies Financial Group began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 target price for the company. Stifel Nicolaus began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $28.00 target price on the stock. Wall Street Zen downgraded Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Finally, Leerink Partnrs upgraded Maplight Therapeutics to a “strong-buy” rating in a research note on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $31.00.

Maplight Therapeutics Stock Up 11.5%

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.